Efficacy and indications of rituximab reported in our and previously published studies
| Authors, years | Number of patients | Indications for RTX | Efficacy for lymphoma | Efficacy for systemic features | Efficacy for objective dryness | Efficacy for subjective dryness | Adverse events |
|---|---|---|---|---|---|---|---|
| IRR, infusion-related reaction; NM, not mentioned; NR, not relevant; pSS, primary Sjögren’s syndrome; RTX, rituximab; SSR, serum sickness-like reaction. | |||||||
| *Four patients are common between the two studies. | |||||||
| Somer, 2003 13 | 1 | Lymphoma | Yes | NR | Yes | Yes | No |
| Voulgarelis, 2004 14 | 4 | Lymphoma (4/4) | 4/4 (100%) | 3/3 (100%) | NM | NM | 2/4 (50%) |
| 2 IRR | |||||||
| Harner, 2004 15 | 1 | Lymphoma | Yes | NR | NM | Yes | NM |
| Ramos-Casals, 2004 16 | 2 | Lymphoma (2/2) | Yes | NR | NM | NM | NM |
| Pijpe, 2005 17 | 1 | Lymphoma | Yes | NR | Yes | Yes | No |
| Gottenberg, 2005* 9 | 6 | Lymphoma (2/6) | 1/2 (50%) | NR | N (0/2) | 3/6 (50%) | 2/6 (33%) |
| Systemic features (4/6) | NR | 4/4 (100%) | 1 SSR, 1IRR | ||||
| Ahmadi-Simab, 2005 11 | 1 | Scleritis | NR | Yes | NM | NM | NM |
| Pijpe, 200518 | 15 | Lymphoma (7/15) | 3/7 (43%) | 28.6% (2/7) | Yes | 6/14 (43%) | |
| Early pSS (8/15) | NM | 100% (7/7) | 3 SSR, 2 IRR | ||||
| Ring, 2005 19 | 1 | Renal tubular acidosis | NR | No | Yes | Yes | No |
| Voulgarelis, 2006 20 | 6 | Lymphoma (6/6) | 6/6 (100%) | 3/6 (50%) | NM | No | 2/6 (33%) |
| Present study* | 16 | Lymphoma (5/16) | 4/5 (80%) | NR | 2/16 (18%) | 5/16 (36%) | 4/16 (25%) |
| Systemic features (11/16) | NR | 9/11 (82%) | 2 SSR, 2 IRR | ||||